康缘药业(600557) - 2021 Q1 - 季度财报

Financial Performance - Operating income for the period was CNY 861,784,479.53, representing a year-on-year increase of 5.27%[14] - Net profit attributable to shareholders was CNY 83,997,468.15, an increase of 4.61% compared to the same period last year[14] - The company reported a net profit excluding non-recurring gains and losses of CNY 79,169,802.55, a decrease of 34.19% year-on-year[14] - Basic and diluted earnings per share remained at CNY 0.14, unchanged from the previous year[14] - Total revenue for Q1 2021 reached ¥861,784,479.53, an increase of 5.5% compared to ¥818,613,341.47 in Q1 2020[33] - Net profit for Q1 2021 was ¥85,495,310.26, representing a 5.3% increase from ¥81,334,498.60 in Q1 2020[33] - The net profit attributable to shareholders of the parent company was CNY 83,997,468.15, up from CNY 80,298,659.40 in the same period last year, reflecting a growth of 8.5%[35] - The total comprehensive income for Q1 2021 was CNY 82,798,148.61, slightly higher than CNY 82,377,580.36 in Q1 2020[38] - The total profit for Q1 2021 was CNY 97,409,586.60, compared to CNY 96,914,800.42 in Q1 2020, showing a marginal increase of 0.5%[37] Cash Flow - Net cash flow from operating activities was negative CNY 26,924,256.95, a decrease of 117.09% year-on-year[14] - In Q1 2021, Jiangsu Kangyuan Pharmaceutical Co., Ltd. reported a net cash flow from operating activities of -26,924,256.95 RMB, a significant decrease compared to 157,513,321.75 RMB in Q1 2020[40] - The total cash inflow from operating activities was 857,748,455.94 RMB, down from 1,018,482,137.62 RMB in the same period last year, representing a decline of approximately 15.8%[40] - Cash outflow from operating activities increased to 884,672,712.89 RMB, compared to 860,968,815.87 RMB in Q1 2020, indicating a rise of about 2.3%[40] - The company recorded cash inflow from investment activities of 406,669,359.73 RMB, a substantial increase from 175,361,384.85 RMB in Q1 2020, marking an increase of approximately 131.9%[41] - Cash outflow from investment activities rose to 505,241,214.53 RMB, compared to 289,170,128.65 RMB in the previous year, reflecting an increase of about 74.8%[41] - The net cash flow from financing activities was -209,310,692.11 RMB, worsening from -42,647,053.58 RMB in Q1 2020[41] - The ending balance of cash and cash equivalents was 434,005,410.32 RMB, slightly up from 409,298,835.69 RMB in Q1 2020[41] - The company received 191,000,000.00 RMB from borrowings in Q1 2021, a decrease from 533,090,000.00 RMB in the same quarter of the previous year, representing a decline of approximately 64.3%[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,966,485,088.21, a decrease of 2.48% compared to the end of the previous year[14] - Total assets decreased to ¥5,966,485,088.21 from ¥6,118,508,375.52, indicating a decline in overall asset value[25] - Total liabilities decreased to ¥1,614,265,134.40 from ¥1,791,779,701.68, showing a reduction in the company's obligations[26] - The company's total equity increased to ¥4,352,219,953.81 from ¥4,326,728,673.84, reflecting a slight growth in shareholder value[26] - Current assets totaled ¥2,709,789,134.83, down 4.8% from ¥2,847,131,528.89 in the previous year[28] - Total liabilities amounted to ¥1,497,335,792.57, a decrease of 10.8% from ¥1,678,776,208.25 at the end of 2020[30] Shareholder Information - The number of shareholders at the end of the reporting period was 34,527, with Jiangsu Kangyuan Group holding 29.71% of shares[17] - The top ten shareholders collectively held 61.73% of the total shares, indicating a concentrated ownership structure[17] Research and Development - Research and development expenses for Q1 2021 were ¥103,601,243.98, an increase of 22% compared to ¥84,940,200.44 in Q1 2020[33] - The company's R&D expenses increased to CNY 95,628,713.38, compared to CNY 80,059,086.75 in Q1 2020, marking a rise of 19.4%[37] Financial Ratios - The weighted average return on equity was 2.00%, a decrease of 0.02 percentage points from the previous year[14] - Financial expenses decreased by 57.41% to ¥3,345,537.72 from ¥7,855,949.26, mainly due to a reduction in short-term borrowings[21] - The financial expenses decreased significantly to CNY 3,072,993.06 from CNY 6,886,989.93 in the previous year, a reduction of 55.4%[37]